Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents

Chin Med J (Engl). 2009 Jul 20;122(14):1704-8.
No abstract available

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biphasic Insulins
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Female
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Insulin / administration & dosage
  • Insulin / analogs & derivatives*
  • Insulin Aspart
  • Insulin, Isophane
  • Male
  • Middle Aged
  • Treatment Outcome

Substances

  • Biphasic Insulins
  • Hypoglycemic Agents
  • Insulin
  • insulin aspart, insulin aspart protamine drug combination 30:70
  • Insulin, Isophane
  • Insulin Aspart